The US erectile dysfunction therapeutic product market stretches into the OTC space with regulatory approval of UK firm Futura Medical plc’s Eroxon gel containing water, ethanol, propylene glycol, glycerin and carbomer potassium hydroxide.
The Food and Drug Administration approved Futura’s Eroxon through its De Novo regulatory pathway, provided in Sec. 513(f)(2) of the...







